BEN GREENSTEINSenior Visiting Research Fellow, Pain Management Service, Royal Free Hospital, London

Select Guide Rating

• Pharmacokinetics. Pharmacodynamics. Clinical trials. Receptor types. Autonomic nervous system 1. Autonomic nervous system 2. Autonomic nervous system 3. Neuromuscular junction. Myasthenia. 5-HT. Eiconasoids. Peptides and proteins as drugs. Systems targeted by drugs. Diuretics. Drugs and the heart I: heart failure. Drugs and the heart II: myocardial infarction (heart attack). Drugs and the heart III: antidysrhythmic drugs. Drugs and the heart IV: angina pectoris. Drugs and the heart V: antiplatelet drugs. Anticoagulants I: heparin. Anticoagulants II: oral anticoagulants. Fibrinolytic and antifibrinolytic drugs. Hypertension I: introduction. Hypertension II: treatment. Inflammation I: introduction. Inflammation II: NSAIDS. Inflammation III: steroidal anti-inflammatory drugs. Inflammation IV: disease-modifying antirheumatic drugs (DMARDS). Inflammation V: gout, scleroderma and raynaud’s phenomenon. Paracetamol. Opioid analgesics. Local anaesthetics. General anaesthetics. Parkinson’s disease. Epilepsy. Alzheimer’s disease. Antidepressant drugs. Anxiolytic drugs. Anti-infective agents. Malignancy.

BEN GREENSTEINSenior Visiting Research Fellow, Pain Management Service, Royal Free Hospital, London

Select Guide Rating

• Pharmacokinetics. Pharmacodynamics. Clinical trials. Receptor types. Autonomic nervous system 1. Autonomic nervous system 2. Autonomic nervous system 3. Neuromuscular junction. Myasthenia. 5-HT. Eiconasoids. Peptides and proteins as drugs. Systems targeted by drugs. Diuretics. Drugs and the heart I: heart failure. Drugs and the heart II: myocardial infarction (heart attack). Drugs and the heart III: antidysrhythmic drugs. Drugs and the heart IV: angina pectoris. Drugs and the heart V: antiplatelet drugs. Anticoagulants I: heparin. Anticoagulants II: oral anticoagulants. Fibrinolytic and antifibrinolytic drugs. Hypertension I: introduction. Hypertension II: treatment. Inflammation I: introduction. Inflammation II: NSAIDS. Inflammation III: steroidal anti-inflammatory drugs. Inflammation IV: disease-modifying antirheumatic drugs (DMARDS). Inflammation V: gout, scleroderma and raynaud’s phenomenon. Paracetamol. Opioid analgesics. Local anaesthetics. General anaesthetics. Parkinson’s disease. Epilepsy. Alzheimer’s disease. Antidepressant drugs. Anxiolytic drugs. Anti-infective agents. Malignancy.

BEN GREENSTEINSenior Visiting Research Fellow, Pain Management Service, Royal Free Hospital, London

Select Guide Rating

• Pharmacokinetics. Pharmacodynamics. Clinical trials. Receptor types. Autonomic nervous system 1. Autonomic nervous system 2. Autonomic nervous system 3. Neuromuscular junction. Myasthenia. 5-HT. Eiconasoids. Peptides and proteins as drugs. Systems targeted by drugs. Diuretics. Drugs and the heart I: heart failure. Drugs and the heart II: myocardial infarction (heart attack). Drugs and the heart III: antidysrhythmic drugs. Drugs and the heart IV: angina pectoris. Drugs and the heart V: antiplatelet drugs. Anticoagulants I: heparin. Anticoagulants II: oral anticoagulants. Fibrinolytic and antifibrinolytic drugs. Hypertension I: introduction. Hypertension II: treatment. Inflammation I: introduction. Inflammation II: NSAIDS. Inflammation III: steroidal anti-inflammatory drugs. Inflammation IV: disease-modifying antirheumatic drugs (DMARDS). Inflammation V: gout, scleroderma and raynaud’s phenomenon. Paracetamol. Opioid analgesics. Local anaesthetics. General anaesthetics. Parkinson’s disease. Epilepsy. Alzheimer’s disease. Antidepressant drugs. Anxiolytic drugs. Anti-infective agents. Malignancy.